Evidence map›Paper›PMID 41821003›Full record

ArticleJournal of translational medicine2026

The PI3K-AKT pathway mediates the imbalance of bone marrow macrophage polarization in patients with immune thrombocytopenia.

Meng-Zhu Shen, Hong-Yan Zhao, Ya-Ting Yu, Xiao-Dong Mo, Hai-Xia Fu, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang, Yuan Kong

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meng-Zhu Shen *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Hong-Yan Zhao *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Ya-Ting YuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Xiao-Dong MoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Hai-Xia FuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Yuan KongPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China. successky@163.com.ORCID 0000-0001-5594-2642

Funding

Beijing Medical Award Foundation YXJL-2024-0039-0055Key Program of the National Natural Science Foundation of China 82530009National Key R&D Program of China 2021YFA1100900, 2022YFA1103300National Natural Science Foundation of China 82270229, 82570263
6 · The paper itself

Abstract

backgroundImmune thrombocytopenia (ITP), characterized by accelerated destruction and insufficient production of platelets, is commonly thought to be an immune-mediated disorder. The unsatisfactory treatment outcomes associated with the disorder indicate that the pathogenic mechanism underlying ITP requires further investigation. M1 macrophages (MФs) have inhibitory effects on haematopoietic stem cells (HSCs) and megakaryocytes (MKs), whereas M2 MФs have opposite effects. However, whether aberrant MΦ polarization in bone marrow (BM) is involved in the occurrence of ITP remains elusive.

methodsCRISPR/Cas9 technology was used to construct BM MФ-specific PI3K-knockout mice, and RNA sequencing (RNA-seq) was performed on the sorted MKs. The functions of BM MKs were evaluated by apoptosis, platelet production, and the percentage of MK ploidy. M1/M2 MΦ polarization; the PI3K–AKT pathway in MΦs; the phagocytosis, migration, HSC-supporting and MK-supporting abilities of BM MΦs were evaluated. The cytokines in the BM plasma or culture supernatant were detected by ELISA.

resultsCompared with control mice, BM MФ-specific PI3K-knockout mice manifested an abnormal M1/M2 ratio and a sharp decrease in megakaryopoiesis and platelet production. RNA-seq indicated that the activity levels of the platelet activation pathway and its initiator (vWF-GPIb) were decreased in the MKs of the PI3K-knockout mice. The results were subsequently validated in clinical cohorts. Compared with those in healthy controls (HCs), impaired megakaryopoiesis and increased BM M1/M2 ratio with decreased levels of p-PI3K and p-AKT in MФs were observed in patients with ITP. Moreover, dysfunctional BM-MФs from patients with ITP could be restored by TPO in vitro. Mechanistically, vascular endothelial growth factor (VEGF) seemed to be the pivotal mediator in the crosstalk whereby MФs influenced MK maturation by increasing vWF secretion.

conclusionsOur findings revealed that increased BM M1/M2 MФ ratio with downregulation of the PI3K–AKT pathway is associated with impaired haematopoiesis, which may be related to the occurrence of ITP. Moreover, we found that TPO improved the functions of BM MФs from patients with ITP by restoring MФ polarization in vitro, which may partially explain why patients with ITP respond better to corticosteroid combined with TPO therapy.

Indexed as

Bone MarrowBone Marrow CellsCell PolarityMacrophagesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPurpura, Thrombocytopenic, IdiopathicSignal TransductionAdultAnimalsBlood PlateletsCytokinesFemaleHumansMaleMegakaryocytesCytokinesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktImmune thrombocytopeniaMegakaryocytopoiesisMΦ polarizationPI3K–AKT pathwayThrombopoietin

Identifiers

PMID41821003
PMCPMC13094248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.